JHOP - June 2021 Vol 11, No 3

Ellen Madarang, PharmD, BCOP; Leslie Gallardo, PharmD, BCPS; Terrence Bradley, MD

Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis

Katherine P. Morgan, PharmD, BCOP, CPP; Yujiao Sun, PharmD; Allison Deal; Jared Weiss, MD; Amber Cipriani, PharmD, BCOP

Jessica M. Tran, PharmD, BCPS; Ni-Chi Wu, PharmD, BCOP, BCPS; Rajkumar J. Sevak, PhD, RPh; Pankaj Gupta, MD, FACP

Pharmacy Resident–Led Medication Reconciliation and Patient Education Service in Adults with Leukemia Receiving Anticancer Oral Agents: A Pilot Study

Lily Y. Jia, PharmD, BCOP; Jessie Signorelli, PharmD, BCOP; Samantha O. Luk, PharmD, BCOP; E. Bridget Kim, PharmD, BCPS, BCOP; Gayle C. Blouin, PharmD, BCOP

FDA Oncology Update

Lumakras First FDA-Approved Therapy for Advanced or Metastatic NSCLC with KRAS G12C Mutation

Rybrevant First FDA-Approved Therapy for NSCLC with EGFR Exon 20 Insertion Mutations

Zynlonta First FDA-Approved CD19-Directed Therapy for Large B-Cell Lymphoma

Jemperli First FDA-Approved Immunotherapy for Advanced Endometrial Cancer with dMMR Biomarker

Keytruda Received FDA Approval for First-Line Treatment of HER2-Positive Advanced Gastric Cancer

Opdivo First FDA-Approved Immunotherapy for First-Line Treatment of Advanced Gastric Cancer

Trodelvy Receives New Indication for Advanced Urothelial Cancer

Sarclisa Receives New Indication for Relapsed or Refractory Multiple Myeloma

From the Literature

Daily Aspirin Does Not Lower Colorectal Cancer Risk When Started After Age 70

Adjuvant Nivolumab Therapy Prolongs Disease-Free Survival in Patients with Esophageal Cancer

New Data Reveal Mismatched Need and Supply of Oncology Physicians and Pharmacists in America

Symptom Management Overview

How I Treat Anemia Associated with Lower-Risk Myelodysplastic Syndromes

Brenna Rowen, PharmD, BCOP

HOPA Highlights

The Impact of Racial Disparities in Cancer Care: Racism a Risk Factor for Poor Clinical Outcomes

Eliminating Structural Racism in Oncology Pharmacy: Individual and Organizational Responsibility

New Opportunities for Pharmacists in Clinical Trials and Drug Development After COVID-19

Immunotherapy Continues to Transform the Treatment Landscape for Advanced Non–Small-Cell Lung Cancer

Cancer Pain Management and the Opioid Conundrum: Optimizing Outcomes, Minimizing Risks

Managing Thromboembolism in Patients with Cancer: Which Are the Preferred Anticoagulants?